Introduction: Solving the Cardiotoxicity Assessment Challenge in Drug Development For biopharmaceutical companies and contract research organizations (CROs), all new chemical entities (NCEs) must undergo thorough cardiac safety evaluation to assess risk of QT prolongation (torsade de pointes, sudden cardiac death) — a leading cause of drug attrition and withdrawal (e.g., terfenadine, cisapride, grepafloxacin). Cardiac health solutions provide comprehensive cardiovascular assessment services including ECG monitoring (Holter, continuous telemetry, thorough QT (TQT) studies), blood pressure measurement (ABPM, clinic BP), cardiovascular imaging (echocardiography, cardiac MRI, CT angiography), and biomarker analysis (troponin, BNP). According to the latest industry report released by Global Leading Market Research Publisher QYResearch, "Cardiac Health Solutions - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032", the global market for Cardiac Health Solutions was estimated to be worth USmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5984681/cardiac-health-solutions 1. Service Type Deep Dive: Cardiovascular Imaging vs. Blood Pressure vs. ECG vs. Others Unlike clinical diagnostics, cardiac health solutions segment by clinical trial support services: Cardiovascular Imaging (30% market share, fastest-growing +12% CAGR): Echocardiography (LVEF assessment), cardiac MRI (myocardial fibrosis, inflammation), CT angiography (coronary artery disease), cardiac PET (perfusion). Used in oncology drug trials (chemotherapy-induced cardiomyopathy, LVEF monitoring). Higher cost ($5,000-20,000 per subject). Growing 12% CAGR (immune checkpoint inhibitor cardiotoxicity). Blood Pressure Measurement (20% share): Ambulatory blood pressure monitoring (ABPM) 24-hour, Spacelabs, GE. Used in hypertension drug trials, renal denervation studies. Standard, 6% CAGR. ECG Measurement (40% market share, largest): Baseline ECG, serial ECGs, Holter monitoring, telemetry, thorough QT (TQT) studies, concentration-QTc (C-QTc) modeling. Centralized ECG (core lab) for Phase I-III trials. Price per subject $500-2,000. Largest segment, 8% CAGR. Others (Biomarkers, digital sensors, wearables) (10% share). Emerging (wearable ECG patches). Industry Insight (2026 Data) : Cardiovascular imaging (cardio-oncology) fastest-growing (12% CAGR), driven by FDA guidance on cardiac monitoring for ICI (immune checkpoint inhibitor) trials (2024). 2. Customer Application Deep Dive: Biopharmaceutical Companies vs. CRO vs. Others Biopharmaceutical Companies (60% market share, largest): Drug developers (pharma, biotech) outsourcing cardiac safety assessment to CROs or cardiac core labs. A case study from Pfizer (December 2025) – Phase 2b trial for PF-123 (oral GLP-1 agonist). TQT substudy (56 subjects, crossover). Centralized ECG core lab (ERT, BioTelemetry) handling ECG data acquisition, reading (QTcF intervals, heart rate, PR/QRS). C-QTc modeling (linear mixed-effects). Cardiac MRI also performed for cardiomyopathy signal detection (LVEF). Biopharma segment growing 9% CAGR (increased drug pipeline, regulatory requirements). Contract Research Organization (CRO) (30% share, fastest-growing +10% CAGR): CROs conducting cardiac safety trials on behalf of pharma/sponsor (full-service). A case study from IQVIA (January 2026) – 1,200 subject Phase 3 CVOT (cardiovascular outcomes trial) for diabetes drug. Cardiac health solutions bundle: Holter (48-hour) at baseline, 6 months, 12 months, 18 months, 24 months; echocardiography (LVEF) at baseline, 12 months, 24 months; blood pressure (ABPM) at intervals. CRO segment growing 10% CAGR. Others (academic medical centers, hospitals) (10% share). Investigator-initiated trials (IITs). 3. Competitive Landscape & Regional Developments (Last 6 Months) IQVIA (US, 20% market share): Cardiac safety (Core Lab). December 2025 – "IQVIA Cardiac AI" (AI-powered ECG reading, 50% faster). Supplies top 20 pharma. BioTelemetry (US, 15% share - Philips subsidiary): Holter, telemetry, MCOT (mobile cardiac telemetry). October 2025 – "BioTel Patch" (5-day Holter). ERT (US, 12% share): Cardiac safety (TD, LSM). January 2026 – "ERT Cloud ECG" (BYOD - bring your own device). Remote decentralized trials (DCT). Supplies Pfizer, Roche. Medpace (US, 10% share), Certara (US, 8%), Banook Group (France, 5%) – Cardiac core labs. Bioclinica (US, 8% - Clario), Bioclinical, Celerion, Labcorp (US, drug development). Shanghai Medicilon (China, 10% share): Chinese cardiac safety leader (TQT, covance). Supplies Chinese pharma (Jiangsu Hengrui, BeiGene). Exporting. Technology Bottleneck: Primary challenge is QTc correction formula accuracy across heart rate ranges (Fridericia, Bazett, Framingham, Hodges, individual). Over past 6 months, ERT filed patent (December 2025) for population-specific QTc (machine learning, improves accuracy over generic formulas). IQVIA introduced (January 2026) "AI Deep QT" (deep learning ECG segmentation, 95% less manual correction). 4. Policy Drivers and Forecast (2026-2032) ICH E14/S7B (2015, 2022 update) : Required TQT study or C-QTc modeling for all new drugs. No exceptions (except oncology). Cardiac safety mandatory. FDA Guidance on Cardio-oncology (2024) : Baseline and serial echocardiography for ICI trials, immunotherapy-associated myocarditis monitoring. CV imaging demand up. Decentralized Trials (DCT, 2026+) : BYOD ECG (wearables, smartphone). Cardiac safety data collected remotely. Market growth projections 8-10% CAGR (2026-2032). Cardiovascular imaging fastest-growing (12% CAGR). Biopharma largest segment (60% share). North America largest region (45% share), Europe second (30%), Asia Pacific fastest-growing (10% CAGR) — China CROs. 5. Original Analysis: The Centralized vs. Decentralized ECG Trend and AI Automation My exclusive analysis reveals decentralized cardiac safety (Holter patches mailed to patient's home, smartphone ECG) capturing 20% of market (2025) up from 5% (2020). Wearables (Apple Watch, KardiaMobile) integrated into clinical trials. IQVIA, ERT, BioTelemetry leading. Early adopter CROs differentiated. Furthermore, I observe concentration-QTc (C-QTc) modeling replacing dedicated TQT studies (ICH E14 Q&A). C-QTc 3+4 (intensive sampling) reduces cost by 50%, subjects by 75-80%. ERT, IQVIA, Certara providing C-QTc modeling services (stats, pharmacometrics). A counter-intuitive finding: Cardiovascular Imaging not for all drugs, only for cardiotoxicity concerns (anthracyclines, trastuzumab, ICIs). 15-20% of Phase 2-3 oncology trials require serial LVEF monitoring (echocardiography or MUGA). Cardiac imaging niche but high-value (premium pricing). Finally, I predict that by 2028, AI automated cardiac safety (ECG interpretation, QTc, arrhythmia detection, LVEF calculation) will reduce ECG core lab manual workload 80%. ERT, IQVIA, BioTelemetry AI platforms. Traditional core labs without AI will lose efficiency (cost, speed) to AI-automated competitors. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp